Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI118725

Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene.

D R Booth, S Y Tan, S E Booth, G A Tennent, W L Hutchinson, J J Hsuan, N F Totty, O Truong, A K Soutar, P N Hawkins, M Bruguera, J Caballería, M Solé, J M Campistol, and M B Pepys

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Find articles by Booth, D. in: PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Find articles by Tan, S. in: PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Find articles by Booth, S. in: PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Find articles by Tennent, G. in: PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Find articles by Hutchinson, W. in: PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Find articles by Hsuan, J. in: PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Find articles by Totty, N. in: PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Find articles by Truong, O. in: PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Find articles by Soutar, A. in: PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Find articles by Hawkins, P. in: PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Find articles by Bruguera, M. in: PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Find articles by Caballería, J. in: PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Find articles by Solé, M. in: PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Find articles by Campistol, J. in: PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Find articles by Pepys, M. in: PubMed | Google Scholar

Published June 15, 1996 - More info

Published in Volume 97, Issue 12 on June 15, 1996
J Clin Invest. 1996;97(12):2714–2721. https://doi.org/10.1172/JCI118725.
© 1996 The American Society for Clinical Investigation
Published June 15, 1996 - Version history
View PDF
Abstract

We report a Spanish family with autosomal-dominant non-neuropathic hereditary amyloidosis with a unique hepatic presentation and death from liver failure, usually by the sixth decade. The disease is caused by a previously unreported deletion/insertion mutation in exon 4 of the apolipoprotein AI (apoAI) gene encoding loss of residues 60-71 of normal mature apoAI and insertion at that position of two new residues, ValThr. Affected individuals are heterozygous for this mutation and have both normal apoAI and variant molecules bearing one extra positive charge, as predicted from the DNA sequence. The amyloid fibrils are composed exclusively of NH2-terminal fragments of the variant, ending mainly at positions corresponding to residues 83 and 92 in the mature wild-type sequence. Amyloid fibrils derived from the other three known amyloidogenic apoAI variants are also composed of similar NH2-terminal fragments. All known amyloidogenic apoAI variants carry one extra positive charge in this region, suggesting that it may be responsible for their enhanced amyloidogenicity. In addition to causing a new phenotype, this is the first deletion mutation to be described in association with hereditary amyloidosis and it significantly extends the value of the apoAI model for investigation of molecular mechanisms of amyloid fibrillogenesis.

Version history
  • Version 1 (June 15, 1996): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts